Cyranoski D, Sipp D, Mallik S, Rasko JEJ. Too little, too soon: Japan's experiment in regenerative medicine deregulation.
Cell Stem Cell 2023;
30:913-916. [PMID:
37419104 DOI:
10.1016/j.stem.2023.06.005]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2022] [Revised: 05/15/2023] [Accepted: 06/12/2023] [Indexed: 07/09/2023]
Abstract
In 2013, Japan established a conditional approval pathway for cell and gene therapies. Our analysis of the four products approved via this pathway identifies evidence suggesting shortcomings in safety and efficacy data submitted by the sponsors and raises concerns about whether this pathway is delivering on its promise.
Collapse